| Literature DB >> 19391115 |
Hiromu Sato1, Keiko Amagai, Rie Shimizukawa, Yoshitaka Tamai.
Abstract
C57BL/6 (B6)-derived embryonic stem (ES) cells are not widely used to generate knockout mice despite the advantage of a well-defined genetic background because of poor developmental potential. We newly established serum- and feeder-free B6 ES cells with full developmental potential by using leukemia inhibitory factor (LIF) and 6-bromoindirubin-3'-oxime (BIO), a glycogen synthase kinase-3 (GSK3) inhibitor. BIO treatment significantly increased the expression levels of 364 genes including pluripotency markers such as Nanog and Klf family. Unexpectedly, by aggregating or microinjecting those ES cells to each eight-cell-stage diploid embryo, we stably generated germline-competent ES-derived mice. Furthermore, founder mice completely derived from female XO, heterozygous, or homozygous mutant B6 ES cells were directly available for intercross breeding and phenotypic analysis. We hereby propose that serum- and feeder-free B6 ES cells stimulated with LIF plus GSK3 inhibitor are valuable for generating mouse models on B6 background. Copyright 2009 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19391115 PMCID: PMC2726955 DOI: 10.1002/dvg.20514
Source DB: PubMed Journal: Genesis ISSN: 1526-954X Impact factor: 2.487
Comparison of Developmental Potential Among Various ES Cells Cultured with 10 U/ml (L10), 1000 U/ml LIF (L1000), 2 mM BIO (BIO), or 40 mM PD98059 (PD)
| ES cells | No. of live offsprings | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ES cell contribution in coat color | ||||||||||||
| Strain | No. of passages | Genotype | Culture condition | Host embryo strain (ploidy) | Method | No. of embryos transferred | Total | 0% | <100% | 100% | Rate of 100% ES-derived oat-color mice in live offsprings (%) | Germline transmission |
| B6 (TB6-2) | 8 | +/+ | Serum 1 Feeder cells 1 L1000 | ICR (4N) | Aggregation | 427 | 2 | 0 | 0 | 2 | 100.0 | n.d. |
| B6 | 12 | +/+ | L10 | ICR (2N) | Aggregation | 88 | 43 | 43 | 0 | 0 | 0.0 | n.d |
| B6 | 12 | +/+ | L10 + BIO | ICR (2N) | Aggregation | 100 | 15 | 12 | 0 | 3 | 20.0 | n.d. |
| B6 | 12 | +/+ | L 1000 | ICR (2N) | Aggregation | 87 | 16 | 8 | 3 | 5 | 31.3 | n.d |
| B6 | 12 | +/+ | L 1000+PD | ICR (2N) | Aggregation | 63 | 10 | 8 | 0 | 2 | 20.0 | 2/2(100%) |
| B6 | 12 | +/+ | L 1000 + BIO | ICR (2N) | Aggregation | 111 | 12 | 1 | 0 | 11 | 91.7 | 1/1(100%) |
| B6 | 12 | +/+ | L 1000 + BIO + PD | ICR (2N) | Aggregation | 63 | 16 | 1 | 0 | 15 | 93.8 | 4/4(100%) |
| B6 | 12 | +/+ | L 1000 + BIO + PD | ICR (4N) | Aggregation | 75 | 18 | 0 | 0 | 18 | 100 | 2/2(100%) |
| B6 | 12 | +/+ | L 1000 + BIO + PD | ICR (2N) | Conventional injection | 44 | 6 | 1 | 0 | 5 | 83.3 | n.d. |
| B6 | 12 | +/+ | L 1000 + BIO + PD | ICR (2N) | Laser-assited injection | 60 | 8 | 1 | 0 | 7 | 87.5 | n.d. |
| V6.5 (B6/129 F1 hybrid) | 18 | +/+ | Serum 1 Feeder cells 1 L1000 | ICR (4N) | Aggregation | 270 | 19 | 0 | 0 | 19 | 100.0 | n.d |
| V6.5 | 22 | +/+ | L1000 + BIO | ICR (2N) | Aggregation | 42 | 10 | 0 | 0 | 10 | 100.0 | 2/2 (100%) |
| V6.5 | 22 | +/+ | L1000 1 BIO 1 PD | ICR (2N) | Aggregation | 42 | 8 | 0 | 0 | 8 | 100.0 | 2/2(100%) |
| B6: Targeted (#48) | 16 | +/− | L1000+BIO | ICR(2N) | Aggregation | 60 | 4 | 0 | 0 | 4 | 100.0 | 2/2(100%) |
| B6 | B6: Targeted (#C5) | +/− | L1000 + BIO | ICR(2N) | Aggregation | 120 | 2 | 1 | 0 | 1 | 50.0 | n.d. |
| B6: Targeted (#F1) | 16 | +/− | L1000+BIO | ICR(2N) | Aggregation | 84 | 6 | 0 | 0 | 6 | 100.0 | 2/2(100%) |
| B6: XO (#2C7) | 16 | +/+ | L1000 + BIO + PD | ICR (2N) | Aggregation | 80 | 6 | 1 | 0 | 5 | 83.3 | 2/2(100%) |
| B6: XO (#2G3) | 16 | +/+ | L1000 + BIO + PD | ICR (2N) | Aggregation | 105 | 4 | 0 | 0 | 4 | 100.0 | n.d. |
| V6.5: Targeted (#16–16) | 27 | −/− | Serum + Feeder cells + L1000 | ICR (4N) | Aggregation | 90 | 4 | 0 | 0 | 4 | 100.0 | n.d. |
| V6.5: Targeted (#16–16) | 30 | −/− | L1000+BIO | ICR(2N) | Aggregation | 60 | 5 | 1 | 1 | 18 | 94.7 | 2/2 (100%) |
| B6: Targeted (#B14) | 22 | −/− | L1000+BIO | ICR(2N) | Aggregation | 60 | 5 | 1 | 1 | 3 | 60.0 | n.d. |
FIG. 1Establishment of serum- and feeder-free B6 ES cells by using LIF and BIO. (a) Morphology (left) and alkaline phosphatase activity (right) of serum- and feeder-free B6 ES cells treated with 1000 U/ml LIF alone. (b) Alkaline phosphatase activity of B6 ES cells cultured for 5 days under the serum- and feeder-free condition. (c) Cell growth assay. Relative cell proliferation was measured as a standard at Day 0. Error bars are standard deviations (n = 6). ***P > 0.0001, t-test, between 1000 U/ml LIF and 1000 U/ml LIF plus 2 μM BIO. (d) GFP expression under Oct4 promoter in serum- and feeder-free B6 ES cells cultured for 5 days. Scale bar: 100 μm.
FIG. 2Upregulation of self-renewal and pluripotency markers in serum- and feeder-free B6 ES cells stimulated by BIO treatment. (a) Scatter plots showing a comparison of global gene expression between 1000 U/ml LIF alone and 1000 U/ml LIF plus 2 μM BIO culture conditions, as determined by DNA microarrays (n = 3). Lines indicate the linear equivalent and two-fold changes in gene expression levels between the samples. (b) Quantitative RT-PCR analyses. Error bars are standard deviations (n = 4). (c) Immunofluorescence analyses of the serum- and feeder-free B6 ES cells stained for Nanog and DAPI (nuclei). Scale bar: 50 μm.
FIG. 3Serum- and feeder-free B6 ES cells in LIF plus BIO have the ability to differentiate into the whole body. WT (+/+) (a and b left side) and leptin receptor KO (−/−) (b right side) mice on B6 background were directly generated from WTand leptin receptor KO ES cells in 1000 U/ml LIF plus 2 μM BIO by aggregating with each eight-cell-stage diploid embryo. ICR mice were used as recipients for embryo transplantation. By using genomic DNA (c) and total RNA (d) of the founder mice, contamination of host ICR cells were examined with quantitative PCR of the leptin receptor.